

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Metyrapone

November 21, 2023

Therapeutic category

Other hormone preparations (including antihormone preparations)

Reagents for various function tests

Non-proprietary name

Metyrapone

Safety measure

PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions):

Revised language is underlined.

Current		Revision	
8. IMPORTANT PRECAUTIONS <Cushing's syndrome> (N/A) (N/A)		8. IMPORTANT PRECAUTIONS <Cushing's syndrome> <u>Prolonged QT may occur. An electrocardiogram test should be performed as necessary.</u> <u>Hypokalaemia may occur. Patients should be carefully monitored through methods such as performing tests.</u>	
11. ADVERSE REACTIONS 11.2 Other Adverse Reactions		11. ADVERSE REACTIONS 11.2 Other Adverse Reactions	
Circulation	Hypotension, hypertension	Circulation	Hypotension, hypertension, <u>prolonged QT</u>
(N/A)	(N/A)	<u>Metabolism</u>	<u>Hypokalaemia</u>

Note: Designated as a drug requiring preparation of a Drug Guide for Patients

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp